Market access for expensive rare disease medications in CEE countries is very challenging and as such difficult to arrange from company headquarters abroad without having a relevant local expertise in each individual country. Small and mid-size companies simply cannot afford to build its direct presence in each country of CEE....
Clinical operations have never faced a more challenging environment than the one they are currently facing, with the projected cost of bringing a medication to market at $2.5 billion and the likelihood of success of getting to the market from phase 1 at less than 10%....
The healthcare ecosystem is riddled with blind spots when it comes to data. These blind spots and lack of visibility result in compromised outcomes, creating vulnerabilities particularly when a patient leaves the hospital. While payers and their claims data offer patient treatment information...
The life sciences sector must reinvent itself to move toward a data-driven, patient-centric value network since it is at a crossroads. The driving force behind this transition is technology. It alters healthcare, medicine, patient access to life science discoveries, and patient communications with the industry....